GPT and colitis: During the observation period, grade 3 or 4 immune‐related adverse events, defined as severe or potentially life‐threatening toxicities requiring intervention and hospitalization, occurred in 14 patients (10.4%), including 7 (50%) cases of colitis, 5 (35.7%) cases of dermatological adverse events, 3 (21.4%) cases of pneumonitis, and 1 (7.1%) case of hepatic adverse event (increased levels of alanine aminotransferase and aspartate transaminase).